GSK returns rights to Anacor antibiotic

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will return to Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) all rights for antibiotic GSK2251052. In February, GSK suspended enrollment in all trials of GSK2251052 following a microbiological finding of resistance in a small number of patients in a Phase IIb trial to treat complicated urinary tract infections (cUTI). Since then, GSK conducted additional preclinical research and subsequently decided to discontinue development. Anacor declined to provide details while GSK could not be reached (see BioCentury Extra, Feb. 6). ...